Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):335-42. doi: 10.1016/j.clml.2014.01.007. Epub 2014 Feb 7.

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Author information

1
Division of Cancer Medicine, Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: jwestin@mdanderson.org.

Abstract

The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose metabolism, translational regulation of protein synthesis, cell proliferation, apoptosis, and survival. Aberrations in the PI3K pathway are among the most frequently observed in cancer, and include amplifications, rearrangements, mutations, and loss of regulators. As a net result of these anomalies, the PI3K pathway is activated in many malignancies, including in Hodgkin and non-Hodgkin lymphomas, and yields a competitive growth and survival advantage, increased metastatic ability, and resistance to conventional therapy. Numerous inhibitors targeting various nodes in the PI3K pathway are undergoing clinical development, and their current status in lymphoma will be the focus of this review.

KEYWORDS:

Akt; Lymphoma; PI3K; Review; Signalling; Targeted; Therapy; mTor

PMID:
24650973
PMCID:
PMC4125533
DOI:
10.1016/j.clml.2014.01.007
[Indexed for MEDLINE]
Free PMC Article

Publication type, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center